Claims
- 1. A Lyme disease vaccine comprising a pharmaceutically acceptable carrier and a vector containing DNA encoding substantially pure OspA protein of Borrelia burgdorferi, or an immunogenic fragment thereof, whereby said vector expresses substantially pure OspA protein of Borrelia burgdorferi or an immunogenic fragment thereof, and does not express other Borrelia proteins; and, wherein said vector comprises a nonpathogenic microorganism.
- 2. The Lyme disease vaccine of claim 1 wherein said DNA encodes substantially pure OspA protein of Borrelia burgdorferi.
- 3. The Lyme disease vaccine of claim 1 wherein said DNA encodes an immunogenic fragment of said substantially pure OspA protein of Borrelia burgdorferi.
- 4. The Lyme disease vaccine of any one of claims 1 to 3 wherein said DNA includes a nucleotide sequence encoding a signal peptide for which there is an amino acid recognition sequence.
- 5. The Lyme disease vaccine of claim 4 wherein said recognition sequence is L-z-z-C, wherein each z independently from the other represents a small neutral amino acid, and said substantially pure OspA protein of Borrelia burgdorferi is cleaved at this site in the expressing of said DNA.
- 6. The Lyme disease vaccine of claim 5 wherein said z is selected from the group consisting of isoleucine and alanine.
- 7. The Lyme disease vaccine of claim 4 wherein said signal peptide has a C-terminal region containing an amino acid sequence L-I-x-C wherein x is a non-charged amino acid residue.
- 8. The Lyme disease vaccine of claim 7 wherein x is alanine.
- 9. The Lyme disease vaccine according to any one of claims 1 to 3 wherein said substantially pure OspA protein of Borrelia burgdorferi includes an amino acid sequence (I/L)-x-x-x-x-(I/L)-x-L-A-L-I-x-C wherein x is a non-charged amino acid residue and (I/L) denotes an amino acid residue selected from the group consisting of isoleucine and leucine.
- 10. The Lyme disease vaccine according to any one of claims 1 to 4 wherein said substantially pure OspA protein of Borrelia burgdorferi is a lipoprotein.
- 11. The Lyme disease vaccine of claim 10 wherein said substantially pure OspA protein of Borrelia burgdorferi has a fatty acylated cysteine as a first amino acid.
- 12. The Lyme disease vaccine according to any one of claims 1 to 3 wherein said substantially pure OspA protein of Borrelia burgdorferi contains an amino acid sequence selected from the group consisting of: Lys-Gly-Lys-Asn-Lys-Asp, Ser-Lys-Lys-Thr-Lys-Asp, and Lys-Ala-Asp-Lys-Ser-Lys.
- 13. The Lyme disease vaccine of claim 1 wherein said DNA has a nucleotide sequence encoding an amino acid sequence shown in FIG. 5 for the 31 kd substantially pure OspA protein of the New York strain B31 (ATCC 35210) of Borrelia-burgdorferi.
- 14. The Lyme disease vaccine of claim 1 wherein said substantially pure OspA protein is the 31 kd OspA protein of the New York strain B31 (ATCC 35210) of Borrelia burgdorferi.
- 15. The Lyme disease vaccine according to any one of claims 13 or 14 wherein said substantially pure OspA protein of Borrelia burgdorferi is a lipoprotein.
- 16. A Lyme disease vaccine comprising a pharmaceutically acceptable carrier and a vector; said vector consisting essentially of DNA encoding substantially pure OspA protein of Borrelia burgdorferi, or an immunogenic fragment thereof, whereby said vector expresses substantially pure OspA protein of Borrelia burgdorferi or an immunogenic fragment thereof; and, wherein said vector comprises a nonpathogenic microorganism.
- 17. The Lyme disease vaccine of claim 16 wherein said DNA encodes substantially pure OspA protein of Borrelia burgdorferi.
- 18. The Lyme disease vaccine of claim 16 wherein said DNA encodes an immunogenic fragment of said substantially pure OspA protein of Borrelia burgdorferi.
- 19. The Lyme disease vaccine of any one of claims 16 to 18 wherein said DNA includes a nucleotide sequence encoding a signal peptide for which there is an amino acid recognition sequence.
- 20. The Lyme disease vaccine of claim 19 wherein said recognition sequence is L-z-z-C, wherein each z independently from the other represents a small neutral amino acid, and said substantially pure OspA protein of Borrelia burgdorferi is cleaved at this site in the expressing of said DNA.
- 21. The Lyme disease vaccine of claim 20 wherein said z is selected from the group consisting of isoleucine and alanine.
- 22. The Lyme disease vaccine of claim 19 wherein said signal peptide has a C-terminal region containing an amino acid sequence L-I-x-C wherein x is a non-charged amino acid residue.
- 23. The Lyme disease vaccine of claim 22 wherein x is alanine.
- 24. The Lyme disease vaccine according to any one of claims 16 to 18 wherein said substantially pure OspA protein of Borrelia burgdorferi includes an amino acid sequence (I/L)-x-x-x-x-(I/L)-x-L-A-L-I-x-C wherein x is a non-charged amino acid residue and (I/L) denotes an amino acid residue selected from the group consisting of isoleucine and leucine.
- 25. The Lyme disease vaccine according to any one of claims 16 to 18 wherein said substantially pure OspA protein of Borrelia burgdorferi is a lipoprotein.
- 26. The Lyme disease vaccine of claim 25 wherein said substantially pure OspA protein of Borrelia burgdorferi has a fatty acylated cysteine as a first amino acid.
- 27. The Lyme disease vaccine according to any one of claims 16 to 18 wherein said substantially pure OspA protein of Borrelia burgdorferi contains an amino acid sequence selected from the group consisting of: Lys-Gly-Lys-Asn-Lys-Asp, Ser-Lys-Lys-Thr-Lys-Asp, and Lys-Ala-Asp-Lys-Ser-Lys.
- 28. The Lyme disease vaccine of claim 16 wherein said DNA has a nucleotide sequence encoding an amino acid sequence shown in FIG. 5 for the 31 kd substantially pure OspA protein of the New York strain B31 (ATCC 35210) of Borrelia burgdorferi.
- 29. The Lyme disease vaccine of claim 16 wherein said substantially pure OspA protein is the 31 kd OspA protein of the New York strain B31 (ATCC 35210) of Borrelia burgdorferi.
- 30. The Lyme disease vaccine according to any one of claims 28 or 29 wherein said substantially pure OspA protein of Borrelia burgdorferi is a lipoprotein.
Priority Claims (1)
Number |
Date |
Country |
Kind |
5902/88 |
Oct 1988 |
DKX |
|
Parent Case Info
This application is a division of application Ser. No. 08/375,993 , filed Jan. 20 , 1995, now U.S. Pat. No. 5,688,512 which in turn is a divisional of application Ser. No. 08/079,601, filed Jun. 23, 1993, now U.S. Pat. No. 5,523,089, which in turn is a continuation of application Ser. No. 07/924,798, filed Aug. 6, 1992, now abandoned which in turn is a continuation of application Ser. No. 07/422,881, filed Oct. 18, 1989, abandoned.
US Referenced Citations (5)
Foreign Referenced Citations (1)
Number |
Date |
Country |
2025597 |
Sep 1990 |
CAX |
Divisions (2)
|
Number |
Date |
Country |
Parent |
375993 |
Jan 1995 |
|
Parent |
079601 |
Jun 1993 |
|
Continuations (2)
|
Number |
Date |
Country |
Parent |
924798 |
Aug 1992 |
|
Parent |
442881 |
Oct 1989 |
|